Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma

Secondary in the breast is a very rare condition but may occur usually from contralateral breast and from others like lymphoma, melanoma, ovarian tumors, and pulmonary malignancies and malignancies of the gastrointestinal and genitourinary tract. Among the primary diseases, melanoma is notorious and unpredictable in its metastatic potentiality and organ of dissemination. There are few reported cases with metastatic melanoma in the breast. We report a case of metastatic deposits in the breasts of a 45year-old lady who presented with bilateral breast lumps with axillary lymphadenopathy having no primary site of melanoma. Journal of Surgical Sciences (2015) Vol. 19 (2) : 72-74

Download Full-text

Approach to Metastatic Melanoma

10.2310/7800.16079 ◽

2017 ◽

Author(s):

Alexandra Gangi ◽

Jonathan S Zager

Keyword(s):

Surgical Treatment ◽

Metastatic Melanoma ◽

Distant Metastasis ◽

Systemic Therapy ◽

Newly Diagnosed ◽

Hepatic Perfusion ◽

Melanoma Patients ◽

Almost All ◽

In Transit ◽

Percutaneous Hepatic Perfusion

Over several decades, the incidence of melanoma has steadily risen. Although a minority of newly diagnosed melanoma patients present with distant metastasis at initial diagnosis, approximately 30% of patients eventually develop metastatic disease as a consequence of disease progression. Although almost all organs can be involved, the most frequent sites of disease are either local or regional recurrences. This review outlines surgical treatment of recurrent or metastatic melanoma, including regional therapies, as well as management with systemic therapy. This review contains 5 figures, 6 tables and 66 references Key words: in-transit disease, limb infusion, metastatectomy, metastatic melanoma, percutaneous hepatic perfusion, regional therapy, systemic therapy

Download Full-text

Intracranial Treatment in Melanoma Patients with Brain Metastasis Is Associated with Improved Survival in the Era of Immunotherapy and Anti-BRAF Therapy

Cancers ◽

10.3390/cancers13174493 ◽

2021 ◽

Vol 13 (17) ◽

pp. 4493

Author(s):

Céline Dalmasso ◽

Cécile Pagès ◽

Léonor Chaltiel ◽

Vincent Sibaud ◽

Elisabeth Moyal ◽

...

Keyword(s):

Prognostic Factors ◽

Metastatic Melanoma ◽

Systemic Treatment ◽

Checkpoint Inhibitors ◽

Locally Advanced ◽

Treatment Patterns ◽

Newly Diagnosed ◽

Mutation Status ◽

Multivariable Analyses ◽

Melanoma Patients

Metastatic melanoma patients are at high risk of brain metastases (BM). Although intracranial control is a prognostic factor for survival, impact of local (intracranial) treatment (LT), surgery and/or radiotherapy (stereotactic or whole brain) in the era of novel therapies remains unknown. We evaluated BM incidence in melanoma patients receiving immune checkpoint inhibitors (ICI) or anti-BRAF therapy and identified prognostic factors for overall survival (OS). Clinical data and treatment patterns were retrospectively collected from all patients treated for newly diagnosed locally advanced or metastatic melanoma between May 2014 and December 2017 with available BRAF mutation status and receiving systemic therapy. Prognostic factors for OS were analyzed with univariable and multivariable survival analyses. BMs occurred in 106 of 250 eligible patients (42.4%), 64 of whom received LT. Median OS in patients with BM was 7.8 months (95% CI [5.4–10.4]). In multivariable analyses, LT was significantly correlated with improved OS (HR 0.21, p < 0.01). Median OS was 17.3 months (95% CI [8.3–22.3]) versus 3.6 months (95% CI [1.4–4.8]) in patients with or without LT. LT correlates with improved OS in melanoma patients with BM in the era of ICI and anti-BRAF therapy. The use of LT should be addressed at diagnosis of BM while introducing systemic treatment.

Download Full-text

Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study

Cancer Management and Research ◽

10.2147/cmar.s187208 ◽

2018 ◽

Vol Volume 11 ◽

pp. 339-346 ◽

Cited By ~ 2

Author(s):

Dongxiao Zhang ◽

Yinjun Dong ◽

Xiubin Sun ◽

Shuanghu Yuan ◽

Jinming Yu

Keyword(s):

Metastatic Melanoma ◽

Primary Tumor ◽

Population Based ◽

Newly Diagnosed ◽

Matched Study

Download Full-text

Approach to Metastatic Melanoma

10.2310/cgso.16079 ◽

2017 ◽

Author(s):

Alexandra Gangi ◽

Jonathan S Zager

Keyword(s):

Surgical Treatment ◽

Metastatic Melanoma ◽

Distant Metastasis ◽

Systemic Therapy ◽

Newly Diagnosed ◽

Hepatic Perfusion ◽

Melanoma Patients ◽

Almost All ◽

In Transit ◽

Percutaneous Hepatic Perfusion

Over several decades, the incidence of melanoma has steadily risen. Although a minority of newly diagnosed melanoma patients present with distant metastasis at initial diagnosis, approximately 30% of patients eventually develop metastatic disease as a consequence of disease progression. Although almost all organs can be involved, the most frequent sites of disease are either local or regional recurrences. This review outlines surgical treatment of recurrent or metastatic melanoma, including regional therapies, as well as management with systemic therapy. This review contains 5 figures, 6 tables and 66 references Key words: in-transit disease, limb infusion, metastatectomy, metastatic melanoma, percutaneous hepatic perfusion, regional therapy, systemic therapy

Download Full-text